Aims/hypothesis A recent genome-wide association study identified the SLC30A8 rs13266634 polymorphism encoding an Arg325Trp polymorphism in the zinc transporter protein member 8 (ZnT-8) to be associated with type 2 diabetes. Here, we investigate whether the polymorphism is related to altered insulin release in response to intravenous and oral glucose loads in non-diabetic offspring of type 2 diabetic patients. Methods We genotyped SLC30A8 rs13266634 in 846 nondiabetic offspring of type 2 diabetic patients from five different white populations: Danish (n=271), Finnish (n=217), German (n=149), Italian (n=109) and Swedish (n=100). Participants were subjected to both IVGTTs and OGTTs, and measurements of insulin sensitivity. Results Homozygous carriers of the major type 2 diabetes C risk-allele showed a 19% decrease in first-phase insulin release (0-10 min) measured during the IVGTT (CC 3,624± 3,197; CT 3,763±2,674; TT 4,478±3,032 pmol l −1 min −1 , mean±SD; p=0.007). We found no significant genotype effect on insulin release measured during the OGTT or on estimates of insulin sensitivity. Conclusions/interpretation Of European non-diabetic offspring of type 2 diabetes patients, 46% are homozygous carriers of the Arg325Trp polymorphism in ZnT-8, which is known to associate with type 2 diabetes. These diabetesprone offspring are characterised by a 19% decrease in firstphase insulin release following an intravenous glucose load, suggesting a role for this variant in the pathogenesis of pancreatic beta cell dysfunction.
Introduction
Type 2 diabetes is a common and often disabling condition [1] resulting from a complex interaction between genetic and environmental factors that cause two major pathophysiological features: impaired pancreatic beta cell function and insulin resistance [2] . Recently, a genome-wide association study showed that an Arg325Trp polymorphism in SLC30A8 (rs13266634) associates with type 2 diabetes with an OR of 1.52±0.31, p=5×10 −7 [3] . Similar findings have been provided by other independent genome-wide association studies [4, 5] and replicated in four case-control studies [6] [7] [8] [9] . SLC30A8, located on chromosome 8q24.11, is exclusively expressed in pancreas and mainly in the beta cell [10] . SLC30A8 encodes a zinc transporter protein member 8 (ZnT-8), which is localised in insulin secretory granules [10] and is important for maturation, storage and secretion of insulin from beta cells [11, 12] . One study showed that the major risk C allele of rs13266634, which confers increased risk of type 2 diabetes, was associated with decreased insulin release during an OGTT in 3,982 middle-aged people of the general Danish population [4] . In contrast, two other studies of 1,276 and 921 non-diabetic individuals, respectively, found that risk-allele carriers did not show reduced insulin release after an oral glucose load [13, 14] . However, in a sub sample of 150 individuals from the latter study, reduced insulin release upon intravenous glucose stimulation was demonstrated [14] . We aimed to investigate whether SLC30A8 rs13266634 has an impact on insulin release following intravenous or oral glucose loads in a relatively large study sample of European non-diabetic offspring of parents with type 2 diabetes.
Methods
Participants All participants included in this study were healthy non-diabetic offspring of parents with type 2 diabetes.
For inclusion, one of the parents had to have type 2 diabetes and the other parent normal glucose tolerance evaluated by an OGTT or a lack of history of type 2 diabetes. The probands were recruited from five study centres in Europe. Altogether, 846 non-diabetic offspring were included in the study as follows: Danish (n=271), Finnish (n=217), German (n=149), Italian (n=109) and Swedish (n=100). Clinical and biochemical characteristics of the study population are shown in Table 1 .
The study protocol was approved by appropriate Institutional Review Boards and was in accordance with the Helsinki Declaration II. All study participants gave informed consent.
Biochemical and anthropometric measures All study centres followed the same protocol. Fasting blood samples were drawn after 12 h of fasting followed by an OGTT (75 g glucose) to evaluate glucose tolerance status and OGTT-related insulin release (samples for measurement of plasma glucose and serum insulin were drawn at 0, 30, 90 and 120 min). On the second occasion after 12 h of fasting an IVGTT was performed to determine the first-phase (0-10 min) insulin release. A bolus of glucose (300 mg/kg in a 50% solution) was given within 30 s into the antecubital vein. Samples for the measurement of plasma glucose and insulin (arterialised venous blood) were drawn at −5, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50 and 60 min. At 60 min after the glucose bolus a hyperinsulinaemic-euglycaemic clamp was initiated (insulin infusion: 240 pmol m −2 min −1 for 120 min) to evaluate insulin sensitivity [15] . Glucose was clamped at 5.0 mmol/l for the next 120 min by infusion of 20% glucose at various rates according to glucose measurements performed at 5 min intervals. In the Copenhagen centre, the euglycaemic clamp was not performed. Instead, all individuals underwent a 33-point tolbutamide-modified, frequently sampled IVGTT. Insulin sensitivity index (Si) was calculated using the Bergman MINMOD computer programme [16] . Blood pressure was measured in a sitting position after a 5 min rest with a mercury sphygmomanometer. Height and weight were measured to the nearest 0.5 cm and 0.1 kg, Data are mean±SD Plasma glucose and serum insulin levels were measured in the fasting state and at 2 h after an OGTT respectively. BMI was calculated as weight (kg) divided by height (m) squared. Glucose was measured by each centre and determined by standard laboratory methods. Because plasma insulin was measured by different methods (except for the Gothenburg centre, which had insulin measured in Tübingen), the assay applied in Tübingen (micro-particle enzyme immunoassay; Abbott Laboratories, Tokyo, Japan) was selected as a reference assay. Catanzaro, Copenhagen and Kuopio centres sent 40 to 100 fasting and post-glucose challenge plasma insulin samples to Tübingen for parallel analyses. Plasma insulin levels from these three centres were converted to plasma insulin levels corresponding to the Tübingen assay by linear regression analysis.
Genotyping Screening of rs13266634 was performed with the TaqMan Allelic Discrimination Assays (Applied Biosystems, Foster City, CA, USA). The genotype distributions in the individual study samples are given in Table 2 . The overall genotyping success rate was 100%; re-screening of 6.3% of samples gave 100% identical results. Genotype distributions obeyed Hardy-Weinberg equilibrium.
Statistical analysis Data analyses were performed using Statistical Package for Social Science (SPSS, Chicago, IL, USA) version 14.0. The results for continuous variables are given as means±SD. A value of p<0.05 was considered to be significant. Insulin levels were logarithmically transformed prior to statistical analysis. The incremental area under the insulin curve during an IVGTT was calculated by the trapezoidal method. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as described earlier [17] . The differences between the groups were assessed by ANOVA for continuous variables and by the χ 2 test for noncontinuous variables. Linear mixed model analysis was applied to adjust for confounding factors. For mixed model analysis we included the centre and pedigree (coded as a family number) as random factors, the genotype and sex as fixed factors, and age and BMI as covariates.
Results
The SLC30A8 rs13266634 genotype and allele frequencies for the individual EUGENE2 study cohorts are summarised in Table 2 . Although all analyses were corrected for recruitment centre, we compared genotype and allele frequencies and found a significant difference between cohorts. The type 2 diabetes-linked CC genotype of SLC30A8 rs13266634, which had an overall frequency of 46% in non-diabetic offspring of type 2 diabetic patients, was associated with decreased first-phase insulin release during an IVGTT (CC 3,624±3,197, CT 3 (Fig. 1d) . We found no association between the SLC30A8 rs13266634 genotypes and second-phase IVGTT insulin release (Table 3 , Fig. 1d ), OGTT insulin release (Fig. 1b) or insulin sensitivity as measured by a hyperinsulinaemic-euglycaemic clamp, insulin sensitivity index calculated using the Bergman MINMOD computer programme (ESM Table 1 ) or HOMA-IR (Table 3 ). In addition, we did not detect any significant impact of the genotype on plasma glucose levels during the IVGTT or the OGTT (Fig. 1a,c) .
Discussion
In the present study of 846 European participants, each of whom had one type 2 diabetic parent, we demonstrate that homozygous carriers (46% of the examined study population) of the major risk C allele of SLC30A8 are characterised by a 19% decrease in first-phase insulin release during an IVGTT. No differences in insulin release during the second phase of the IVGTT or in insulin sensitivity were shown. Our findings indicate that the findings of previous studies of Genotype data are number (n) of participants with each genotype (% of each group) and major risk-allele frequencies in per cent (95% CI) according to study cohort common, multifactorial forms of type 2 diabetes, for which an association with SLC30A8 Arg325Trp has been consistently documented, are likely to be explained by a gene variant causing pancreatic beta cell dysfunction. A previous study of 3,982 non-diabetic middle-aged people of the general Danish population reported a decrease in insulin release after an oral glucose load among C allele carriers [4] . In contrast, in the present study and in two other studies of 1,276 and 921 non-diabetic individuals, respectively, reduced insulin release after an oral glucose load could not be demonstrated [13, 14] . Interestingly, in a sub-study of 150 healthy individuals in the German study [14] , the C allele was shown to associate with reduced insulin release upon intravenously administered glucose. The discrepancy between the association of SLC30A8 rs13266634 with glucose-stimulated insulin release during the IVGTT and the lack of association with insulin release after an oral glucose load in the same people is unexplained, but might be due to compensatory mechanisms involving increased incretin secretion and/or incretin effect after orally administered glucose. Another possible explanation might be lack of statistical power to detect a beta cell defect upon an oral glucose load. In the total cohort of 846 nondiabetic persons, our data indicate that the effect of the SLC30A8 rs13266634 is less than 18% of a standard deviation.
SLC30A8 encodes a zinc transporter, ZnT-8, which in both humans and mice is exclusively produced in pancreas, mainly in beta cells [10, 18, 19] . It is localised to insulin secretory granules [10, 12, 20] , where it facilitates the accumulation of zinc from the cytoplasm into intracellular vesicles and is implicated in secretion of insulin from beta cells [18, [20] [21] [22] [23] . Our data show that the acute insulin release after an intravenous glucose load is severely reduced, indicating that the function and/or production of ZnT-8 are reduced in carriers of the common risk C-allele of SLC30A8. It is likely that the risk C allele or a tightly linked causative variant also modulates the function of neighbouring Fig. 1 a, cells via paracrine/autocrine interactions. A previous report indicates that zinc released from activated insulin-secreting beta cells is implicated in the suppression of glucagonsecretion in neighbouring alpha cells [24] . It has also been suggested [10, 21, 25] that excessive apoptosis of the pancreatic beta cells is associated with diabetes, and since zinc is a potent inhibitor of apoptosis, zinc depletion by itself can enhance apoptosis in beta cells [21] . Thus, the SLC30A8 C allele might not only cause a decrease in insulin release, but may also lead to decreased beta cell mass via increased apoptosis. In addition, overexpression of SLC30A8 in insulinoma cells has been shown to increase glucose-stimulated insulin secretion [18] . Therefore, stimulating ZnT-8 production and/or activity may potentially be a novel approach in the treatment of type 2 diabetes patients, in whom zinc depletion is likely to participate in both acute and chronic beta cell dysfunction [18] .
In conclusion, in non-diabetic but diabetes-prone European offspring of one type 2 diabetic patient, homozygous carriers of the Arg325Trp polymorphism in ZnT-8 are characterised by a 19% reduced first-phase serum insulin response following an intravenous glucose challenge. This finding underscores the hypothesis that variation in ZnT-8 is a cause of impaired pancreatic beta cell function and thereby modulates insulinaemia.
